Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5 CAD | +4.17% | -3.85% | +69.49% |
05-29 | NurExone Biologic Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-25 | NurExone Biologic Announces OTCQB Listing And DTC Eligibility | MT |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Lior Shaltiel
CEO | Chief Executive Officer | - | 21-03-31 |
Eran Ovadya
DFI | Director of Finance/CFO | - | 22-06-14 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jay Richardson
BRD | Director/Board Member | 78 | 22-01-02 |
Gadi Riesenfeld
BRD | Director/Board Member | 79 | 23-07-05 |
Yoram Drucker
CHM | Chairman | 59 | 19-12-31 |
Oded Orgil
BRD | Director/Board Member | 57 | 22-06-14 |
Lior Shaltiel
CEO | Chief Executive Officer | - | 21-03-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 67,105,428 | 63,578,695 ( 94.74 %) | 0 | 94.74 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+69.49% | 24.39M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- NRX Stock
- Company NurExone Biologic Inc.